(Q36548370)

14 August 2017

1 reference

title

Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct (English)

1 reference

14 August 2017

main subject

acute myeloid leukemia

1 reference

Lazarus HM

1

1 reference

14 August 2017

Rowe JM

series ordinal

2

1 reference

14 August 2017

publication date

27 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

10

1 reference

14 August 2017

page(s)

1673-1682

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404328

14 August 2017

exact match

0 references

cites work

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Palifermin for oral mucositis after intensive therapy for hematologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Graft-versus-host disease in mini-transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors in Older Patients With Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Comorbidity indices in hematopoietic stem cell transplantation: a new report card

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

Nonmyeloablative allogeneic stem cell transplantation using alternative donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Protective conditioning for acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404328

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404328

1 reference

14 August 2017

1 reference